title: Should hepatitis B immunoglobulin therapy be discontinued after HBV reinfection following liver transplantation?
authors.affiliation: Liver Unit, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Safadi
authors.forename: A
authors.initials: A
authors.lastname: E'id
authors.forename: Y
authors.initials: Y
authors.lastname: Ilan
authors.forename: Y
authors.initials: Y
authors.lastname: Ashur
authors.forename: O
authors.initials: O
authors.lastname: Jurim
authors.forename: D
authors.initials: D
authors.lastname: Shouval
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000209:etiology; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
chemical_list: D000914:Antibodies, Viral